Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?

ABSTRACT: There is a new generation of antiobesity drugs in development or just arriving on the scene. First, setmelanotide has been approved for three of the ultrarare genetic conditions that cause obesity-pro-opiomelanocortin deficiency, proprotein convertase subtilisin and kexin type 1 (an important enzyme in the melanocortin pathway) and leptin receptor deficiency. Setmelanotide marks the first in a personalized medicine approach to obesity. Second, semaglutide 2.4 mg once weekly has been submitted to regulators in the United States and the European Union for approval for patients with obesity (body mass index [BMI] ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) and at least one weight related comorbidity. This drug has been studied in five phase 3 clinical trials, four discussed

SUBMITTER: Ryan DH 

PROVIDER: S-EPMC8526285 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature